Inimmune reports initial cancer patient treated in a phase 1 trial with its new TLR7/8 agonist immunotherapy, INI-4001.

Transposon Reports Conclusive Data from Phase 2 Trial of TPN-101 Targeting C9orf72-Linked ALS and/or Frontotemporal Dementia.

Sage Therapeutics and Biogen Reveal Key Findings from Phase 2 KINETIC 2 Trial of SAGE-324 (BIIB124) for Essential Tremor Treatment.

Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.

This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.

Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.

OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.

IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.

Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.

Merck Reveals Preliminary Findings from Phase 2b/3 Study of Clesrovimab (MK-1654), an Experimental Monoclonal Antibody for RSV Prevention in Infants.

FDA Greenlights Samsung Bioepis' EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab).